References 1 Cooper C, Carbone L, Michet CJ et al (1994)

References 1. Cooper C, Carbone L, Michet CJ et al (1994)

Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 21(10):1877–1882PubMed 2. Vosse D, Landewe R, van der Heijde D et al (2009) Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 68(12):1839–1842PubMedCrossRef Selumetinib mw 3. Geusens P, Vosse D, van der Linden S (2007) Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 19(4):335–339PubMedCrossRef 4. Franck H, Meurer T, Hofbauer LC (2004) Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 31(11):2236–2241PubMed 5. Ghozlani I, Ghazi M, Nouijai A et al (2009) Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing see more spondylitis. Bone 44(5):772–776PubMedCrossRef 6. Gratacos J, Collado A, Pons F et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 42(11):2319–2324PubMedCrossRef 7. Lange U, Teichmann J, Strunk J et al (2005) Association of 1.25 vitamin D3 deficiency, disease activity

and low bone mass in ankylosing spondylitis. Osteoporos Int 16(12):1999–2004PubMedCrossRef 8. Maillefert JF, Aho LS, El Maghraoui A et al (2001) Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 12(7):605–609PubMedCrossRef 9. Toussirot E, Ricard-Blum S, Dumoulin G et al (1999) Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology 38(1):21–27PubMedCrossRef 10. El Maghraoui A (2004) from Osteoporosis and ankylosing spondylitis. Joint Bone

Spine 71(4):291–295PubMedCrossRef 11. Lange U, Jung O, Teichmann J et al (2001) Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis. Osteoporos Int 12(12):1031–1035PubMedCrossRef 12. Mermerci Baskan B, Pekin Dogan Y, Sivas F et al (2009) The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis. Rheumatol Int. doi:10.​1007/​s00296-009-0975-7 PubMed 13. Obermayer-Pietsch BM, Lange U, Tauber G et al (2003) Vitamin D receptor initiation codon polymorphism, bone density and inflammatory activity of patients with ankylosing spondylitis. Osteoporos Int 14(12):995–1000PubMedCrossRef 14. Borman P, Bodur H, Bingol N et al (2001) Bone mineral density and bone turnover markers in a group of male ankylosing spondylitis patients: relationship to disease activity. J Clin Rheumatol 7(5):315–321PubMedCrossRef 15. Park MC, Chung SJ, Park YB et al (2008) Bone and cartilage turnover markers, bone mineral density, and radiographic damage in men with ankylosing spondylitis.

This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>